Implications for Public Health Practice
Data from randomized, double-blind clinical trials demonstrated similar rates of SARS-CoV-2 RNA rebound in nirmatrelvir/ritonavir and placebo recipients. These findings support FDA’s determination of safety and efficacy of nirmatrelvir/ritonavir in eligible patients at high risk for severe COVID-19.